Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • Irene (pyrotinib) • albumin-bound paclitaxel • trastuzumab rezetecan (SHR-A1811) • Saitanxin (culmerciclib)

13d

FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)

P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2028 --> Sep 2029 | Trial primary completion date: Dec 2026 --> Dec 2027

13 days ago

Trial completion date • Trial primary completion date

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)

Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Idafang (ivonescimab) • bulumtatug fuvedotin (9MW2821) • AiRuiLi (adebrelimab) • IBI-354 • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)

14d

Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer (clinicaltrials.gov)

P2, N=57, Recruiting, Sun Yat-sen University

14 days ago

New P2 trial

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • HR positive

Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib) • fulvestrant • AiRuiKang (dalpiciclib) • loperamide

14d

A Structured Classification of Pyrotinib-Containing Neoadjuvant Regimens for HER2-Positive Breast Cancer: Efficacy, Safety, and Regimen Selection. (PubMed, Breast Cancer (Dove Med Press))

Existing studies are generally limited by small sample sizes and a lack of long-term survival data, and high-level evidence directly comparing pyrotinib-based strategies with trastuzumab plus pertuzumab is scarce. Future research should prioritize biomarker-driven patient selection, response-adaptive trial designs, and standardized toxicity management to optimize clinical decision-making.

14 days ago

Review • Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive

Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)

16d

The prognostic value of peripheral blood inflammatory markers in patients with HER2-positive metastatic breast cancer treated with pyrotinib. (PubMed, Front Oncol)

Kaplan-Meier survival curve and Cox regression model was used to analyze the effect of different levels of NLR and LDH before T-DM1 treatment on the survival of patients. Elevated NLR and LDH were associated with poor PFS and OS. Future data are needed to validate and update our results.

16 days ago

Journal

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive

Kadcyla (ado-trastuzumab emtansine) • Irene (pyrotinib)

19d

Efficacy and safety of pyrotinib combined with trastuzumab and chemotherapy in patients with HER2-positive locally advanced breast cancer: a multicenter real-world study. (PubMed, Am J Transl Res)

In a real-world setting the addition of pyrotinib to trastuzumab and chemotherapy significantly improved pathological and radiographic responses and prolonged PFS, albeit with an increased but manageable toxicity profile.

19 days ago

Journal • Real-world evidence

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive

Herceptin (trastuzumab) • Irene (pyrotinib)

21d

Pertuzumab Vs. Pyrotinib in Combination With Trastuzumab and Taxanes for First-Line Treatment of HER2+ MBC: A Multicenter Real-World Study. (PubMed, Cancer Med)

THPy may provide PFS benefit over THP in HER2+ MBC, with suggestive advantages in patients with de novo stage IV disease and liver metastasis. A higher frequency of diarrhea and other gastrointestinal toxicities was observed in the THPy regimen.

21 days ago

Clinical • Retrospective data • Journal • Real-world evidence

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive

Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib)

21d

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer (clinicaltrials.gov)

P4, N=500, Not yet recruiting, Peking University People's Hospital

21 days ago

New P4 trial • Real-world evidence

HER-2 positive

Herceptin (trastuzumab) • Perjeta (pertuzumab) • Irene (pyrotinib) • trastuzumab rezetecan (SHR-A1811)

22d

Cost-effectiveness analysis of the treatment pathway after trastuzumab treatment failure in patients with HER2-positive advanced breast cancer: a chinese health system perspective. (PubMed, BMC Health Serv Res)

In the context of the Chinese health system, none of the three alternative regimens-pyrotinib plus capecitabine, T-DM1, and T-DXd-demonstrated cost-effectiveness relative to lapatinib plus capecitabine at the current WTP threshold.

22 days ago

Journal • HEOR • Cost-effectiveness

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive • EGFR positive

lapatinib • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • Irene (pyrotinib)

A real-world study on treatment after TKI progression in HER2-positive MBC. (PubMed, Ther Adv Med Oncol)

All patients received anti-HER2 TKI therapy (including pyrotinib and lapatinib) in 28-day cycles. No unexpected toxic effects were reported. After progression following TKI therapy, T-DXd exhibited notable antitumor activity, although no significant efficacy differences were observed among ADC, mAb, and TKI groups.

1 month ago

Journal • Real-world evidence

HER-2 (Human epidermal growth factor receptor 2)

HER-2 positive

lapatinib • Enhertu (fam-trastuzumab deruxtecan-nxki) • Irene (pyrotinib)